BeiGene And NewBridge Pharmaceuticals Announce Approval In Saudi Arabia Of BRUKINSA (Zanubrutinib) For The Treatment Of Patients With Relapsed Or Refractory Mantle Cell Lymphoma
BRUKINSA is now approved for the treatment of MCL in 11 countries and regions, including the United States, China, Canada, Australia, Brazil, the United Arab Emirates, and Russia
BeiGene and NewBridge Pharmaceuticals are working together to rapidly advance BRUKINSA in the Middle East and North African (MENA) region
BeiGene a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, and NewBridge Pharmaceuticals, a specialty company in the Middle East and North Africa (MENA) regions established to bridge the access gap by partnering with global pharma and biotech companies, today announced that BRUKINSA® (zanubrutinib) has received approval from the Saudi Food and Drug Authority (SFDA) for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. BeiGene and NewBridge Pharmaceuticals are working together to bring BRUKINSA to healthcare providers and people living with MCL in Saudi Arabia and other MENA markets following regulatory approvals.
Top AiThority.com Insights: “Bitcoin Has No Intrinsic Value”. Then What Gives Bitcoin Value?
“Non-Hodgkin’s lymphoma is a leading cause of cancer incidence and mortality in Saudi Arabia, representing a significantly unmet need for those living with diseases, such as MCL. BRUKINSA is a next-generation BTK inhibitor designed to improve tolerability issues often associated with the class and has demonstrated efficacy in clinical trials for patients with relapsed or refractory MCL,” said Dr. Ahmad Absi, Hematology Section Head at the National Guard Health Affairs in Jeddah, Kingdom of Saudi Arabia.
“We are delighted that MCL patients in Saudi Arabia will now have access to BRUKINSA, a potentially best-in-class BTK inhibitor. Driven by our belief—Cancer has no borders. Neither do we, BeiGene is committed to expanding access to high-impact medicines for all patients who need them. With approval in Saudi Arabia and in the United Arab Emirates earlier this year, we are working with NewBridge Pharmaceuticals to bring BRUKINSA to more patients in the MENA region,” commented Mohammed Al-Kapany, Senior Director of New Markets in MENA at BeiGene.
“The approval of BRUKINSA in Saudi Arabia represents an important milestone in our ongoing collaboration with BeiGene. With this differentiated BTK inhibitor now approved in two markets in the MENA region, we are one step closer to reaching patients living with MCL with new treatment options,” remarked Joe Henein, President and CEO of NewBridge Pharmaceuticals.
The recommended dose of BRUKINSA is either 160 mg twice daily or 320 mg once daily, taken orally with or without food. The dose may be adjusted for adverse reactions and reduced for patients with severe hepatic impairment and certain drug interactions.
Recommended AI News: Intelliswift Transforms Itself for The New World – Unveils A New Brand Identity
[To share your insights with us, please write to sghosh@martechseries.com]
Comments are closed.